First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt

J Neurointerv Surg. 2022 May;14(5):495-499. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3.

Abstract

Surgical ventriculoperitoneal shunting remains standard treatment for communicating hydrocephalus, despite persistently elevated infection and revision rates. A novel minimally invasive endovascular cerebrospinal fluid (CSF) shunt was developed to mimic the function of the arachnoid granulation which passively filters CSF from the central nervous system back into the intracranial venous sinus network. The endovascular shunt is deployed via a femoral transvenous approach across the dura mater into the cerebellopontine angle cistern. An octogenarian with intractable hydrocephalus following subarachnoid hemorrhage underwent successful endovascular shunting, resulting in swift intracranial pressure reduction from 38 to <20 cmH2O (<90 min) and resolution of ventriculomegaly. This first successful development of a percutaneous transluminal venous access to the central nervous system offers a new pathway for non-invasive treatment of hydrocephalus and the potential for intervention against neurological disorders.

Keywords: catheter; hydrocephalus; intervention; intracranial pressure; technology.

MeSH terms

  • Aged, 80 and over
  • Biomimetics*
  • Cerebellopontine Angle / surgery
  • Cerebrospinal Fluid Shunts / methods
  • Humans
  • Hydrocephalus* / diagnostic imaging
  • Hydrocephalus* / etiology
  • Hydrocephalus* / surgery
  • Magnetic Resonance Imaging / methods
  • Ventriculoperitoneal Shunt / adverse effects